[G22-13] Nivolumab (adenocarcinoma of the stomach, the gastro-oesophageal junction or the oesophagus) – 2nd Addendum to Commission A21-146
Last updated 19.05.2022
Commission awarded on 12.04.2022 by the Federal Joint Committee (G-BA).
If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.
|Nivolumab (gastric adenocarcinoma, adenocarcinoma of the gastroesophageal junction or the oesophagus) - Benefit assessment according to §35a Social Code Book V